Citadel Advisors - TCR2 THERAPEUTICS INC ownership

TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 84 filers reported holding TCR2 THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of TCR2 THERAPEUTICS INC
ValueSharesWeighting
Q4 2022$273,547
-42.9%
273,876
+3.0%
0.00%
Q3 2022$479,000
-64.6%
265,953
-43.0%
0.00%
Q2 2022$1,353,000
+44.1%
466,422
+37.1%
0.00%
Q1 2022$939,000
-65.3%
340,284
-41.4%
0.00%
Q4 2021$2,706,000
-35.9%
580,701
+17.0%
0.00%
-100.0%
Q3 2021$4,223,000
-43.9%
496,209
+8.2%
0.00%0.0%
Q2 2021$7,526,000
-46.2%
458,696
-27.5%
0.00%
-66.7%
Q1 2021$13,976,000
-60.5%
632,951
-44.6%
0.00%
-66.7%
Q4 2020$35,368,000
+3135.9%
1,143,468
+2026.1%
0.01%
Q3 2020$1,093,000
+728.0%
53,782
+214.9%
0.00%
Q1 2020$132,00017,0770.00%
Other shareholders
TCR2 THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
MPM BioImpact LLC 6,741,964$208,528,00018.01%
MPM ASSET MANAGEMENT LLC 4,050,865$125,293,00017.73%
Consonance Capital Management LP 584,885$71,268,0006.66%
SILVERARC CAPITAL MANAGEMENT, LLC 136,000$4,206,0002.44%
Redmile Group, LLC 2,832,888$87,621,0001.06%
Altium Capital Management LP 73,991$2,289,0000.86%
PFM Health Sciences, LP 775,794$23,995,0000.84%
Soleus Capital Management, L.P. 199,867$6,182,0000.82%
MOODY ALDRICH PARTNERS LLC 123,639$3,824,0000.62%
Sofinnova Investments, Inc. 333,707$10,322,0000.61%
View complete list of TCR2 THERAPEUTICS INC shareholders